Phase I
Clinically advanced vaccine, ACI-35.030, designed to reduce and to prevent the spread and development of Tau pathology
A number of companies reported clinical trial data last week. Here’s a look.
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
PRESS RELEASES